Lexeo Therapeutics, Inc. (LXEO) – What Are Researchers Thinking About This Stock?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned an average recommendation of “Buy” from the eight analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $16.43.

Several research firms have commented on LXEO. Leerink Partners restated an “outperform” rating and issued a $15.00 price target on shares of Lexeo Therapeutics in a report on Wednesday, September 23rd. Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Wall Street Zen raised shares of Lexeo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 19th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Lexeo Therapeutics in a research report on Tuesday, September 22nd. Finally, Chardan Capital raised shares of Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of LXEO. Signaturefd LLC grew its stake in Lexeo Therapeutics by 5,159.1% during the third quarter. Signaturefd LLC now owns 8,362 shares of the company’s stock worth $28,000 after buying an additional 8,203 shares during the period. Legal & General Group Plc purchased a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $32,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Lexeo Therapeutics in the 4th quarter valued at $37,000. Abel Hall LLC purchased a new position in shares of Lexeo Therapeutics in the 3rd quarter valued at $43,000. Finally, Spark Investment Management LLC acquired a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at $70,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $2.80 on Friday. The stock has a fifty day moving average of $3.96 and a two-hundred day moving average of $4.71. The company has a market capitalization of $229.73 million, a price-to-earnings ratio of -2.43 and a beta of 1.63. Lexeo Therapeutics has a fifty-two week low of $2.55 and a fifty-two week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01). On average, analysts forecast that Lexeo Therapeutics will post -1.18 EPS for the current fiscal year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for genetically defined cardiovascular and central nervous system diseases. The company uses adeno-associated virus (AAV) gene-delivery technologies to develop treatments intended to address the underlying causes of disease rather than only manage symptoms.

Lexeo’s pipeline includes investigational programs for conditions such as Friedreich ataxia-associated cardiomyopathy, a serious heart complication of Friedreich ataxia, and genetic forms of neurodegenerative disease.